Clinical Research Focus. 41st Edition

EMA Backs New CAR-T Therapy for Adult Acute Lymphoblastic Leukemia

The EMA has recommended conditional approval of Aucatzyl, a CAR T-cell therapy for adults 26+ with relapsed or refractory B-cell ALL. The treatment reprograms a patient’s own immune cells to target cancer and has shown strong remission results in trials. If approved by the European Commission, it will be the third CAR T option for adult ALL patients in the EU.

Learn more

Prioritizing Quality of Life in Oncology: A Call for Compassionate Care

In his recent Medicina article, Dr. Vlad Bogin, MD, FACP, CEO of Cromos Pharma, emphasizes the importance of integrating palliative care into oncology. He advocates for a patient-centered approach that values quality of life alongside innovative treatments, ensuring that compassion and dignity remain central in cancer care.

Learn more

FDA Approves First Blood Test to Aid Alzheimer’s Diagnosis

The FDA has cleared the first blood test to support Alzheimer’s diagnosis — a major step forward in making detection more accessible. Designed for adults 55+ with cognitive symptoms, the test identifies key biomarkers linked to amyloid plaques, offering a less invasive alternative to PET scans and spinal taps.

Learn more

World Asthma Day 2025: Time to Rethink Respiratory Care

On World Asthma Day 2025, Cromos Pharma underscores the urgent need to modernize respiratory care. Despite asthma and COPD affecting millions globally, treatments have remained largely unchanged for decades, relying heavily on oral steroids that often lead to side effects and relapses. The article advocates for innovative therapies and smarter interventions to address these challenges and improve patient outcomes.

Learn more

NIH Scientists Develop Targeted Gene Delivery Tools for the Brain and Spinal Cord

NIH researchers have created new gene delivery systems that precisely target specific cells in the brain and spinal cord — a major leap for treating conditions like ALS, Parkinson’s, and epilepsy. This breakthrough brings us closer to therapies that are not only powerful, but deeply personal.

Learn more

Image credit: Allen Institute

Genmab’s Rina-S Shows Promising Results in Endometrial Cancer, Advancing to Phase 3 Trial

Genmab’s antibody-drug conjugate, rinatabart sesutecan (Rina-S), has demonstrated a 50% unconfirmed response rate in advanced endometrial cancer patients, surpassing analyst expectations. This encouraging data supports the progression to a Phase 3 trial, highlighting Rina-S’s potential as a new treatment option in a field with limited therapies.

Learn more

Pfizer Strikes $6B Cancer Drug Deal with China’s 3SBio

Pfizer has secured global rights (excluding China) to 3SBio’s experimental bispecific antibody, SSGJ-707, which targets both PD-1 and VEGF pathways. The licensing deal is valued at up to $6 billion, including a $1.25 billion upfront payment and a planned $100 million equity investment in 3SBio.

Learn more

MRI Flags Hidden Heart and Liver Risks Years Before Major Events, Study Finds

In the largest study of its kind, multiorgan MRI revealed that subtle heart and liver impairments can predict major cardiovascular and liver events—years in advance. Liver inflammation, measured by cT1, emerged as a powerful noninvasive marker, spotlighting the need for integrated cardiac-liver screening in at-risk patients.

Learn more